Congratulations to Wuhan YZY Biopharma Co Ltd (2496.HK) on its Successful Listing

Founded in 2010, Wuhan YZY Biopharma Co., Ltd. is a biotechnology company dedicated to developing BsAb-based therapies to treat cancer-associated complications, cancer and age-related ophthalmologic diseases. YZYBIO has persisted in inhouse innovation, laid out and cultivated the field of bispecific antibodies, and developed four innovative platforms, including the self-developed YBODY platform, Check-BODY platform and Nano-YBODY platform, and UVAX platform developed in collaboration with WIV. The company has designed and developed a pipeline of seven clinical-stage drug candidates.

With regard to this listing application, AVISTA Group is honoured to be engaged in providing valuation services in relation to preferred shares, ESOs, convertible bonds and market value of property.

Congratulations again to Wuhan YZY Biopharma Co Ltd (2496.HK) on its successful listing. The issue price is HKD16 per share, and the amount of funds raised is HKD121 million.